

1.0.7 DOC EIA

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE guidelines

Equality impact assessment

Macular degeneration: diagnosis and management of age-related macular degeneration

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

5.0 After Guidance Executive amendments – if applicable (to be completed by appropriate NICE staff member after Guidance Executive)

5.1 Outline amendments agreed by Guidance Executive below, if applicable:
GE requested changes to the recommendations and associated footnotes with regard to pharmacological treatment of AMD with anti-VEGF drugs. These changes do not impact on any identified equality issues and were to ensure that the recommendations are in line with appropriate drug licensing regulations

Approved by Developer: Susan Spiers, Associate Director, Guidelines Update Team

Date: 18.12.17

Approved by NICE quality assurance lead: Christine Carson, Guideline Lead

Date: 05.01.18